Shut Down
CardioDx Stock
CardioDx is a cardiovascular genomic diagnostics company providing clinicians with information to enhance patient care.
Sign up today and learn more about CardioDx Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About CardioDx Stock
CardioDx is a cardiovascular genomic diagnostics company located in Palo Alto, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failures.
Funding History
| July 2006 | $19.0M |
|---|---|
| May 2010 | $34.5M |
| May 2011 | $60.0M |
| August 2011 | $8.0M |
| July 2012 | $30.5M |
| August 2012 | $58.0M |
| July 2014 | $21.0M |
| December 2014 | $35.0M |
| June 2016 | $12.4M |
| January 2017 | $22.5M |
Management
VP, Development
Susan Daniels
Vice President, Technical Operations
Brian Rhees
Chief Commercial Officer
Deborah Kilpatrick
Chief Medical Officer
Mark Monane
Team Member
Anzhelika Rogacheva
Chief Financial Officer
Timothy Henn
Fellow, Head of Research
James Wingrove
Founder & Chief Strategy Officer
David Levison
Vice President, Sales and Marketing
Duane Williams
President and CEO
Khush Mehta
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
